Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PMD Stock Forecast 2025-2026
$2.26
Current Price
$15.74M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PMD Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
PMD Price Momentum
-2.2%
1 Week Change
0.0%
1 Month Change
-11.4%
1 Year Change
+0.9%
Year-to-Date Change
-30.5%
From 52W High of $3.25
+103.6%
From 52W Low of $1.11
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Psychemedics (PMD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PMD and similar high-potential opportunities.
Latest PMD Stock Price Targets & Analyst Predictions
PMD has shown a year-to-date change of 0.9% and a 1-year change of -11.4%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for PMD. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PMD Analyst Ratings
0
Buy
0
Hold
0
Sell
PMD Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $2.26
Latest PMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Psychemedics Corporation (PMD) Competitors
The following stocks are similar to Psychemedics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Psychemedics Corporation (PMD) Financial Data
Psychemedics Corporation has a market capitalization of $15.74M with a P/E ratio of 0.0x. The company generates $20.79M in trailing twelve-month revenue with a -21.9% profit margin.
Revenue growth is -14.6% quarter-over-quarter, while maintaining an operating margin of -19.0% and return on equity of -61.3%.
Valuation Metrics
Market Cap
$15.74M
Enterprise Value
$14.09M
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
0.8x
Growth & Margins
Revenue Growth (YoY)
-14.6%
Gross Margin
+31.4%
Operating Margin
-19.0%
Net Margin
-21.9%
EPS Growth
-11.5%
Financial Health
Cash/Price Ratio
+10.9%
Current Ratio
1.6x
Debt/Equity
32.5x
ROE
-61.3%
ROA
-16.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Psychemedics Corporation (PMD) Business Model
About Psychemedics Corporation
What They Do
Provides drug testing services using hair analysis.
Business Model
The company generates revenue by offering drug testing services that analyze hair samples for various substances, including illegal drugs and prescription medications. Their tests are used by employers for screening potential hires and ongoing employee monitoring, as well as by treatment professionals and law enforcement for monitoring drug use.
Additional Information
Founded in 1986 and based in Dallas, Texas, Psychemedics Corporation employs mass spectrometry for accurate screening and confirmation of drug use. Their testing provides both quantitative data on drug ingestion and historical patterns, which can be critical for understanding long-term substance use.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
116
CEO
Mr. Brian Hullinger
Country
United States
IPO Year
1994
Website
www.psychemedics.comPsychemedics Corporation (PMD) Latest News & Analysis
Latest News
Quick Summary
Psychemedics Corporation (Nasdaq: PMD) announced a 1-for-5,000 reverse stock split followed by a 5,000-for-1 forward stock split, effective December 3, 2024, with trading resuming December 4.
Why It Matters
The stock split indicates significant corporate restructuring, potentially affecting share liquidity and perceived value, which can impact trading behavior and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Psychemedics Corporation (NASDAQ: PMD) reported its third-quarter financial results for the period ending September 30, 2024. Further details on performance were not provided in the excerpt.
Why It Matters
Psychemedics' Q3 financial results can impact stock performance, reflecting growth or challenges in the drug testing market, influencing investor sentiment and future valuations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Psychemedics Corporation (NASDAQ: PMD) has released its first Education Insights Report, expanding its offerings in hair testing for drug abuse.
Why It Matters
Psychemedics' Education Insights Report could enhance its market position, attract new clients, and drive revenue growth, influencing stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Psychemedics Corporation (NASDAQ: PMD) reported its financial results for Q2 2024, ending June 30. Further details on performance were not included in the excerpt.
Why It Matters
Psychemedics' Q2 financial results could indicate growth or challenges, impacting stock performance and investor sentiment regarding the company's market position and future profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Psychemedics Corporation's Board of Directors Approves Plan to Terminate Registration of Its Common Stock
8 months ago
Quick Summary
Psychemedics Corporation plans to delist from Nasdaq and cease common stock registration after a reverse stock split, pending shareholder approval at the 2024 Annual Meeting.
Why It Matters
Psychemedics plans to delist from Nasdaq and cease federal registration, indicating potential financial distress and reduced market visibility, impacting liquidity and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing
10 months ago
Quick Summary
Psychemedics Corporation (NASDAQ: PMD) has released its first Insights Report, analyzing workplace drug trends based on 2023 hair sample data.
Why It Matters
Psychemedics' Insights Report highlights drug trends in the workplace, potentially influencing demand for their services and impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PMD Stock
What is Psychemedics Corporation's (PMD) stock forecast for 2025?
Analyst forecasts for Psychemedics Corporation (PMD) are not currently available. The stock is trading at $2.26.
Is PMD stock a good investment in 2025?
Analyst ratings for PMD are not currently available. The stock is currently trading at $2.26. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PMD stock?
Price predictions from Wall Street analysts for PMD are not currently available. The stock is trading at $2.26.
What is Psychemedics Corporation's business model?
The company generates revenue by offering drug testing services that analyze hair samples for various substances, including illegal drugs and prescription medications. Their tests are used by employers for screening potential hires and ongoing employee monitoring, as well as by treatment professionals and law enforcement for monitoring drug use.
What is the highest forecasted price for PMD Psychemedics Corporation?
Price targets from Wall Street analysts for PMD are not currently available. The stock is trading at $2.26.
What is the lowest forecasted price for PMD Psychemedics Corporation?
Price targets from Wall Street analysts for PMD are not currently available. The stock is trading at $2.26.
What is the overall PMD consensus from analysts for Psychemedics Corporation?
Analyst ratings for PMD are not currently available. The stock is trading at $2.26.
How accurate are PMD stock price projections?
Stock price projections, including those for Psychemedics Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 4:45 PM UTC